CanWell Pharma Announces CAN016, a new generation HER2 Dual-Payload ADC, Receives US FDA IND Approval, for ADC Treated Advanced Solid Tumors
Woburn, Mass. & Guangzhou, China — CanWell Pharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAN016, a novel HER2-targeting dual-payload antibody-drug conjugate (ADC). The company plans to initiate a Phas…
CanWell Pharma Announces Participation in the AACR Annual Meeting 2026.
San Diego, CA – CanWell Pharma is pleased to announce its participation in the AACR Annual Meeting 2026, taking place from April 17–22, 2026, at the San Diego Convention Center. The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health ca…
CANWELL Pharma Received U.S. FDA Orphan Drug Designation for CAN1012 in the Treatment of Soft Tissue Sarcoma
March 3, 2026, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CAN1012, the company’s proprietary IFNα-biased TLR7 agonist, for the treatment of Soft Tissue Sarcoma (STS). CAN1012 is a novel small-molecule IFNα-biased Toll-like receptor 7 (TLR7) agonist developed…
A novel Dual-payload HER2 Targeted ADC, CAN016 as a Clinical Candidate to Overcome Enhertu Resistance
Resistance to ADC Enhertu (DS-8201) therapy presents a significant clinical challenge for patients with HER2-positive cancers. To address this unmet need, we have developed a novel dual-payload ADC (CAN016), conjugating both MMAE and exatecan to a HER2 antibody, based on our proprietary StarLinkerTM…
CanWell Pharma Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, CA – CanWell Pharma is pleased to announce its participation in the 44th Annual J.P. Morgan Healthcare Conference (JPM 2026), taking place from January 12–15, 2026, at the Westin St. Francis Hotel in San Francisco. As one of the world’s most prestigious healthcare investment symposium…
Preliminary Results of CanWell’s CAN1012 (an IFNα-biased TLR7 Agonist) in Combination with Toripalimab was Presented at ESMO 2025
The 2025 European Society for Medical Oncology (ESMO) Annual Congress was held in Oct 17-19, Berlin, Germany. CanWell presented preliminary safety and efficacy data from its Phase 1b/2a clinical trial of CAN1012, a first-in-class IFNα-biased TLR7 agonist, in combination with toripalimab for advanced…
CanWell will Present Latest ADC Program Updates at 16th World ADC in San Diego, CA (Nov 3-6, 2025)
CanWell Pharma will present its latest development progress at the 16th World ADC held on Nov 3-6, 2025, in San Diego, CA. The presentation will be in the form of a poster. The poster will cover the newest research and development updates on company StarLinker dual/tri-payload ADCs, which had made s…
CanWell will Present Clinical Updates on an IFN-α Biased TLR7 Agonist CAN1012 at ESMO 2025 – Annual Meeting (October 17-21, 2025)
CanWell Pharma will present latest updates on company clinical development of CAN1012 at ESMO 2025 – Annual Meeting held on October 17-21, 2025 in Berlin. The presentation will be in a poster format during a poster session at the conference. The poster covers newest clinical study updates on t…